Posts

Posted on

Gabelli Global Utility & Income Trust Continues Monthly Distributions, Declaring Distributions of $0.10 Per Share

Gabelli Global Utility & Income Trust Continues Monthly Distributions, Declaring Distributions of $0.10 Per Share

RYE, N.Y.–(BUSINESS WIRE)–
The Board of Trustees of The Gabelli Global Utility & Income Trust (NYSE American: GLU) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.10 per share for each of January, February, and March 2021.

Distribution Month

Record Date

Payable Date

January

January 14, 2021

January 22, 2021

February

February 11, 2021

February 19, 2021

March

March 17, 2021

March 24, 2021

Under the Fund’s initial distribution policy, the Fund has paid a minimum annual distribution of 6% of the initial public offering price of $20.00 per share (a distribution of $0.10 per share each month).

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2020 would be deemed 100% from paid-in capital on a book basis. The source of the distributions will likely change due to investment activity through the end of the calendar year and this information does not represent what should be reported for tax purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2020 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2020 distributions in early 2021 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. More information regarding the Fund’s distribution policy and other information about the Fund is available by calling 800-GABELLI (800-422-3554) or visiting www.gabelli.com.

About The Gabelli Global Utility & Income Trust

The Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company with $163 million in total net assets whose primary investment objective is to seek a consistent level of after-tax total return for its investors with an emphasis on tax-advantaged dividend income under current tax law. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

NYSE American – GLU

CUSIP – 36242L105

Investor Relations Contact:

Adam Tokar

(914) 457-1079

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Subgroups

– Significant mean reduction of 26.5% in LDL-C with
bempedoic
acid
vs. placebo
in pooled analysis of people who cannot tolerate statins

1

–

– Analysis by
sex
showed
bempedoic
acid significantly lowered LDL-C at week 12 in
males and females
* vs. placebo

2

–

ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced results of pooled data from four of the company’s Phase 3 trials were presented at the virtual American Heart Association Scientific Sessions 2020 (AHA 2020). Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.     

“Women are half of the population, and nearly 10 million patients in the U.S. with high LDL-C levels are not on statins due to tolerability issues,3 yet these groups have been underrepresented in previous medical research,4” said Ashley Hall, Chief Development Officer for Esperion. “Our goal at Esperion is lipid management for everybody, and these analyses show significant LDL-C efficacy and acceptable safety for NEXLETOL in these subgroups.”

In “Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Any Dose of a Statin: Pooled Analysis from Phase 3 Clinical Trials,” (Abstract #P2139) data from a subgroup of more than 580 patients not receiving any dose of a statin showed a significant mean reduction of 26.5% (p< 0.001) in LDL-C by week 12 with NEXLETOL vs. placebo. NEXLETOL was generally well tolerated, with treatment-emergent adverse events (TEAEs) comparable across the bempedoic acid and placebo groups.1

The poster “Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials” (Abstract #P742) showed NEXLETOL significantly lowered LDL-C at week 12 in both sexes compared with placebo for a pooled population of more than 3,600 patients across four studies. LDL-C lowering was numerically greater in females compared with males across both pools of the study: The placebo-corrected mean reduction was 27.7% for females vs. 22.1% for males (interaction p value=0.079) in the statin-intolerant pool, and 21.2% for females vs. 17.4% for males (interaction p value=0.044) in the pool of patients with atherosclerotic cardiovascular disease (ASVCD) and/or heterozygous familial hypercholesterolemia (HeFH) who were receiving background maximally tolerated statin. Bempedoic acid was generally well tolerated by both sexes.2

Approved earlier this year by the U.S. Food and Drug Administration (FDA) and launched at the height of the COVID-19 pandemic, NEXLETOL is the first oral, once-daily, non-statin LDL-C-lowering medicine available to indicated patients in nearly 20 years. The approval of NEXLETOL was supported by a global pivotal Phase 3 LDL-C-lowering program conducted in more than 3,000 patients with ASCVD and/or HeFH. In these studies, NEXLETOL provided an average of 18% placebo-corrected LDL-C lowering when used with moderate or high-intensity statins. The most common (incidence ≥ 2% and greater than placebo) adverse reactions were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia and elevated liver enzymes. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not yet been determined. Please see important safety information below.

*Note: Esperion strives to be inclusive in our both research and our language, and we follow the language guidance outlined in “Reporting Sex, Gender, or Both in Clinical Research?” from The Journal of the American Medicine Association (JAMA).

NEXLETOL® (bempedoic acid) Tablet

NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine approved in the U.S. in nearly 20 years for patients with ASCVD or HeFH. NEXLETOL was approved by the FDA in February 2020.

Indication and Limitation of Use

NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.

Important Safety Information

  • Warnings and Precautions:
    • Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. The risk for gout events with NEXLETOL® (bempedoic acid) tablet was higher in patients with a prior history of gout although gout also occurred more frequently than placebo in patients treated with NEXLETOL™ (bempedoic acid) tablet who had no prior gout history.
    • Tendon rupture has occurred. Discontinue NEXLETOL® (bempedoic acid) tablet at the first sign of tendon rupture. Avoid NEXLETOL® (bempedoic acid) tablet in patients who have a history of tendon disorders or tendon rupture.
  • Adverse Reactions:
  • Drug Interactions:
    • Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.
    • Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Esperion at 833-377-7633 (833 ESPRMED).


Please see the full Prescribing Information for NEXLETOL by clicking here.

Esperion Therapeutics

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding commercialization plans for bempedoic acid tablet. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion’s clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

References

1 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients who Cannot Tolerate Any Does of a Statin: Pooled Analysis from Phase 3 Clinical Trials. Presentation at the American Heart Association Virtual Scientific Sessions 2020. November 2020.

2 Goldberg AC, et al. Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials. Presentation at the American Heart Association Virtual Scientific Sessions 2020. November 2020.

3 ZS Associates primary and secondary research, Sep-Oct 2018. Primary research N = 350 healthcare practitioners

4 J Tamargo, G Rosano, T Walther, J Duarte, A Niessner, JC Kaski, C Ceconi, H Drexel, K Kjeldsen, G Savarese, C Torp-Pedersen, D Atar, BS Lewis, S Agewall, Gender differences in the effects of cardiovascular drugs, European Heart Journal – Cardiovascular Pharmacotherapy, Volume 3, Issue 3, July 2017, Pages 163–182, https://doi.org/10.1093/ehjcvp/pvw042

Contact:
Kaitlyn Brosco
Esperion
[email protected]



Posted on

Gabelli Go Anywhere Trust Declares Fourth Quarter Distribution of $0.05 Per Share

Gabelli Go Anywhere Trust Declares Fourth Quarter Distribution of $0.05 Per Share

RYE, N.Y.–(BUSINESS WIRE)–
The Board of Trustees of The Gabelli Go Anywhere Trust (NYSE American: GGO) (the “Fund”) declared a $0.05 per share cash distribution payable on December 18, 2020 to common shareholders of record on December 11, 2020.

The Fund’s distribution policy is to pay a quarterly distribution of an amount to be determined by the Board of Trustees. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the quarterly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2020 would be deemed 100% from paid-in capital on a book basis This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2020 will be made after year end and can vary from the quarterly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2020 distributions in early 2021 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. More information regarding the Fund’s distribution policy and other information about the Fund is available by calling 800-GABELLI (800-422-3554) or visiting www.gabelli.com.

About Gabelli Go Anywhere Trust

The Gabelli Go Anywhere Trust is a non-diversified, closed-end management investment company whose primary investment objective is total return, consisting of capital appreciation and current income. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

NYSE American: GGO

CUSIP – 36250J109

Investor Relations Contact:

David Schachter

(914) 921-5057

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Other Professional Services Professional Services Finance

MEDIA:

Posted on

Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock offered in the public offering.

Cantor Fitzgerald & Co. is acting as lead bookrunning manager for the offering. H.C. Wainwright & Co. is acting as joint bookrunning manager for the offering. Maxim Group LLC is acting as a co-manager for the offering.

The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriter’s option, if any, of approximately $75.0 million, excluding underwriting discounts and commissions and other offering-related expenses. Assuming the full exercise of the underwriter’s option, gross proceeds would be approximately $86.3 million.

The Company intends to use the net proceeds from the sale of the shares of common stock in the offering to fund a Phase 3 clinical program of sumifilam, the Company’s lead drug candidate, in patients with Alzheimer’s disease, for research and development for the Company’s product candidates and for general corporate purposes.

The offering is expected to close on or about November 17, 2020, subject to satisfaction of customary closing conditions.

The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-237452) relating to the public offering of such securities, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2020 and declared effective by the SEC on May 5, 2020. The offering may be made only by a preliminary prospectus supplement and the accompanying prospectus. Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.

A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to these securities may also be obtained by sending a request to: Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at [email protected] or H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.

For More Information Contact:

Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
[email protected]
(512) 501-2450

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the terms of the proposed public offering, (ii) expected use of the proceeds of the proposed public offering and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, inability of one or more underwriters to participate in the proposed public offering, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other factors are identified and described in more detail in the prospectus supplement to be filed with the SEC in connection with the proposed public offering, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the nine months ended September 30, 2020, which will be incorporated by reference in such preliminary prospectus supplement, and the other documents incorporated by reference in such preliminary prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.



Posted on

World Series of Poker® Main Event ® to Return

Main Event to Begin Online, Live Finale will crown a “World Champion” of Poker for the 51st Consecutive Year

$1 Million “Winner Take All” Prize Money will pit Domestic vs. International Champions for the Title and the Bracelet

PR Newswire

LAS VEGAS, Nov. 13, 2020 /PRNewswire/ — The World Series of Poker (WSOP) today announced plans to host 2020’s hybrid online and live version of the $10,000 No-Limit Hold-Em World Championship, known better to poker players and fans as the Main Event. The Main Event will begin for international players on Sunday, Nov. 29 and domestically on Sunday, Dec. 13.

Due to travel restrictions and out of an abundance of caution for player safety, this year’s format will be unique, where early round play will begin online with one entry on WSOP.com or GGPoker.com, before shifting to a live setting for final table action on two continents. Each “bracket” will pay out prize money to tournament entrants independently. The final table will be a world’s first, as an ultimate heads-up duel for the World Championship, where $1 million in prize money will be on the line courtesy of Caesars Entertainment, Inc. (NASDAQ: CZR) and GGPoker.  The Main Event will be held consistent to the traditional “freeze-out” standards of the Main Event, offering only single entry, as well as the longest levels and deepest stacks ever offered on the online platform.

All in-person tournaments, domestic and international, will be subject to special COVID rules and procedures, the details of which will be published at a later date and will require players to undergo a required health screening prior to live participation.  All participants must agree to abide by all applicable rules.

U.S. residents will be able to play the Main Event on the WSOP.com platform in either New Jersey or Nevada beginning on Sunday, Dec. 13.  The $10,000 event is expected to take two full days to reach the final table, with play being suspended for an overnight break after approximately 12 hours of action. The tournament will be paused when play hits the final table, with the final nine players traveling to Las Vegas for the TV taping and culmination of the tournament to take place at the Rio All-Suite Hotel & Casino, subject to applicable regulatory approval.   

Dates for Domestic Tournament:
Day 1 – Sunday, Dec. 13, 2020
Day 2 – Monday, Dec. 14, 2020, Play down to 9 players
Final Table – Rio All-Suite Hotel & Casino in Las Vegas, Monday, Dec. 28, Play continues to a winner; prize monies paid

International residents eligible to use GGPoker’s popular online poker platform will have three dates from which to choose their starting flight.  Similar to the traditional offline events, players may only choose one date of play.  Similar to the domestic flight, and subject to casino availability, play will be paused for the final nine contestants who will report to King’s Casino in Rozvadov, Czech Republic to play their final table in a live TV taping.  Should travel restrictions or a casino shutdown prevent the live portion from moving forward in December, organizers reserve the right to continue the tournament play online or reschedule to a later date.

Dates for International Tournament:
Day 1A – Sunday, Nov. 29, 2020
Day1B – Saturday, Dec. 5, 2020
Day 1C –   Sunday, Dec. 6, 2020
Day 2, Play down to 9 players, Monday, Dec. 7
Final Table – *King’s Casino, Tuesday, Dec.15, Play down to a winner

*Subject to local regulatory approval

Finally, the winner of the Domestic Tournament and the winner of the International Tournament will meet at the Rio All-Suite Hotel & Casino in Las Vegas, subject to applicable regulatory approval, for a televised showdown on Wednesday, Dec.30, 2020. In addition to any prize monies won by entrants in their respective tournament, WSOP and GGPoker have committed an additional sum of $1 million to the winner of the Heads-Up match along with the Main Event championship bracelet and the title of 2020 World Champion.  *Note, should the international winner be under the age of 21 and thereby ineligible to play in the state of Nevada, organizers reserve the right to change the date and location of the Heads-Up match.

Heads-Up Championship of Domestic Winner vs International Winner:


Wednesday, Dec. 30


Rio All-Suite Hotel & Casino in Las Vegas*

A comprehensive list of satellite events allowing qualification for as little $1 will be available on both WSOP.com and GGPoker.com.  There will also be weekly free-rolls offering $10,000 seat entry for multiple weeks leading up to the tournament.  

To welcome visiting players, Caesars Entertainment will offer special Main Event room rates at several resorts in Nevada and New Jersey. Additionally, new options to deposit money into a WSOP.com account and cash out in person will be available for the first time at Silver Legacy Resort Casino in Reno, NV.  For more information about special hotel rates, and cash at the cage locations, visit wsop.com/mainevent.

Note, players are allowed to create and/or fund their online poker accounts prior to arriving within the state borders of Nevada and New Jersey.  However, they must be geolocated through a CPU of mobile device to be within the state borders to be able to commence any gaming activity.  New players may require document verification and are highly encouraged to register early.

As has been the case each year since 2003, ESPN will air coverage of the 2020 WSOP Main Event featuring Lon McEachern and Norman Chad.

“There must be a World Champion in 2020,” said Ty Stewart, Executive Director of the World Series of Poker. “Poker’s history is too important.  It’s a unique format for the Main Event, but this is a unique year. We want to keep players’ health and safety top of mind and still deliver a great televised showcase for the game we love.”

Added GGPoker Head of Poker Operations Steve Preiss, “We’re very happy to continue to deepen our relationship with WSOP.  It was a huge summer of record-setting action on GGPoker and we’re excited to offer players access to the biggest tournament of all.”

To stay up to date on the latest WSOP news, visit: www.WSOP.com.

About the World Series of Poker

The World Series of Poker® is the largest, richest and most prestigious gaming event in the world, having awarded more than $3.29 billion in prize money and the prestigious gold bracelet, globally recognized as the sport’s top prize. Featuring a comprehensive slate of tournaments in every major poker variation, the WSOP is poker’s longest-running tournament in the world, dating back to 1970.  In 2019, the event attracted 187,298 entrants from 118 different countries to the Rio All-Suite Hotel & Casino in Las Vegas and awarded more than $293 million in prize money. In addition, the WSOP has formed groundbreaking alliances in broadcasting, digital media and corporate sponsorships, while successfully expanding the brand internationally with the advent of WSOP Europe in 2007 and the WSOP Asia-Pacific in 2013 and the WSOP International Circuit Series in 2015. For more information on the WSOP, please visit www.wsop.com.

About GGPoker

GGPoker is one of the world’s leading online poker rooms, with a growing global player base. It offers a range of innovative games and features such as the patented Rush & Cash poker, All-In or Fold, Spin & Gold, integrated staking platform, SnapCam video messaging, the ability to squeeze your hole cards, PokerCraft, and Smart HUD, all designed to enhance gaming experiences and make poker more fun than ever.

Find out more about GGPoker at GGPoker.com and on Facebook and Twitter.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding our strategies, objectives and plans for future development or acquisitions of properties or operations, as well as expectations, future operating results and other information that is not historical information. When used in this press release, the terms or phrases such as “anticipates,” “believes,” “projects,” “plans,” “intends,” “expects,” “might,” “may,” “estimates,” “could,” “should,” “would,” “will likely continue,” and variations of such words or similar expressions are intended to identify forward-looking statements. Although our expectations, beliefs and projections are expressed in good faith and with what we believe is a reasonable basis, there can be no assurance that these expectations, beliefs and projections will be realized. There are a number of risks and uncertainties that could cause our actual results to differ materially from those expressed in the forward-looking statements which are included elsewhere in this press release. These risks and uncertainties include: (a) the effects of the COVID-19 public health emergency, including (i) the extent and duration of the impact of the global COVID-19 public health emergency and measures to contain the public health emergency or mitigate its impact on the Company’s business, financial results and liquidity; (ii) the ability of the Company to modify its operations to comply with various state, tribal and local directives, mandates, and orders; (iii) the impact of actions the Company has undertaken to reduce costs and improve efficiencies to mitigate losses as a result of the COVID-19 public health emergency, which could negatively impact guest loyalty and our ability to attract and retain our employees; and (iv) changes and instability in global, national and regional economic activity and financial market activity as a result of the COVID-19 public health emergency and the impact on consumer discretionary spending and travel; (b) the possibility that the proposed acquisition of William Hill and the announced and proposed dispositions are not consummated on the expected terms or at all; (c) risks related to the Merger of the Company and CEC and the proposed acquisition of William Hill and the integration of their respective businesses and assets; (d) potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the Merger and the proposed acquisition of William Hill; (e) the possibility that the anticipated benefits of the Merger and the proposed acquisition of William Hill, including cost savings and expected synergies, are not realized when expected or at all; (f) risks associated with increased leverage and additional rental expense resulting from debt financing undertaken in connection with the Merger and the proposed acquisition of William Hill and real estate transactions undertaken in connection with the Merger; (g) competitive responses to the Merger and the proposed acquisition of William Hill; and (h) additional factors discussed in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s and CEC’s respective most recent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Other unknown or unpredictable factors may also cause actual results to differ materially from those projected by the forward-looking statements.

In light of these and other risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur. These forward-looking statements speak only as of the date of this press release, even if subsequently made available on our website or otherwise, and we do not intend to update publicly any forward-looking statement to reflect events or circumstances that occur after the date on which the statement is made, except as may be required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/world-series-of-poker-main-event–to-return-301172509.html

SOURCE Caesars Entertainment, Inc.

Posted on

Esports Entertainment Group to Host Third Quarter 2020 Financial Results Call on November 16 at 4:30 p.m. ET

NEWARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) (or the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, will host a conference call and webcast on Monday, November 16, 2020 at 4:30 p.m. ET to answer questions about the Company’s operational and financial highlights for the third quarter of 2020 and recent developments.

Event: Esports Entertainment Group Third Quarter 2020 Conference Call
   
Date: Monday, November 16, 2020
   
Time: 4:30 p.m. Eastern Time
   
Live Call: +1-855-327-6837 (U.S. Toll-Free) or +1-631-891-4304 (International)
   
Webcast:
http://public.viavid.com/index.php?id=142485

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until November 30, 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10011948.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fixed odds wagering, fantasy and pools on various esports events in a licensed, regulated and secure platform at vie.gg and owns and operates online sports book, SportNation.bet. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multiplayer mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports. The Company holds a license to conduct online gambling and 18+ gaming on a global basis in the UK, Ireland, Malta and Curacao. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

Forward Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations 
RedChip Companies, Inc.
Dave Gentry
407-491-4498
[email protected]

Media & Investor Relations Inquiries

[email protected]



Posted on

IIBA Honours 10-Year Corporate Partners with Award Ceremony

The IIBA Corporate Awards Program celebrates organizations around the world who have demonstrated a commitment to supporting training and career development of their teams and have had a significant impact on the business analysis community.

PICKERING, Ontario, Nov. 13, 2020 (GLOBE NEWSWIRE) — The International Institute of Business Analysis (IIBA), the global membership association dedicated to supporting the growth and value of business analysis, was honoured to recognize the contributions of outstanding corporate leaders who have demonstrated exemplary leadership in business analysis in a virtual awards ceremony held November 11, 2020. This year marked the 5th annual celebration of the Corporate Awards Program.

IIBA values its many strong partnerships with organizations around the world committed to fostering relationships that build opportunities for business analysis professionals and helping shape the direction of the practice.

“2020 is especially significant as it marks the 10th anniversary of IIBA’s Corporate Program. We wanted to share a virtual tribute to our corporate honourees in celebration of their outstanding commitment to the practice of business analysis over the past decade,” said Delvin Fletcher, President and CEO of IIBA.

This year, IIBA recognized nine exceptional organizations for demonstrating an unparalleled commitment to thought leadership, adaptability, strategy, and mentoring capturing the quintessence of the IIBA Corporate Awards. View the award presentation here.

Business Analysis in the New Decade

On November 11th, IIBA awarded Nedbank, a South African bank committed to creating value by using financial expertise to give back to their community, with IIBA’s Corporate Leadership Excellence in the Advancement of the Practice of Business Analysis Award recognizing Nedbank’s commitment to transforming business capabilities by adapting and optimizing their business analysis practice. Nedbank has demonstrated leadership excellence via volunteerism and providing sustainable training, certification, and career development opportunities for their business analysis professionals.

The Corporate Program presented the prestigious 10-Year Global Award to eight outstanding organizations for demonstrating a long-term commitment to advancing professional development and training in the business analysis profession.

2020
IIBA
Corporate Award recipients:

  • ANZ, Australia
  • Canadian Pacific Railway, Canada
  • CNO Financial Group, USA
  • Computershare Technology Services, Australia
  • Deloitte, Canada
  • Inland Revenue, New Zealand
  • NTT Data, USA
  • The Westpac Group, Australia

“Congratulations to all our 2020 awardees. This year we celebrated an exceptional group of organizations in recognition of their contributions to advance business analysis,” said IIBA Board of Directors Chair, Keith Ellis. “We are inspired by the exemplary commitment and positive impact these organizations have made to the ongoing professional development of their teams and transformation of the profession over the past decade.”

Learn more about IIBA and how they are working with organizations around the world to deliver better business outcomes through business analysis at iiba.org/business-success.

About IIBA

International Institute of Business Analysis™ (IIBA®) is a professional association dedicated to supporting business analysis professionals to deliver better business outcomes. IIBA connects almost 30,000 Members, over 100 Chapters, and more than 500 training, academic, and corporate partners around the world. As the global voice of the business analysis community, IIBA supports recognition of the profession, networking and community engagement, standards and resource development, and comprehensive certification programs. For more information visit iiba.org.

Media Contact:

Ann Cain
Director, Communications
[email protected]
1-866-789-4422 ext. 146 

Posted on

Arcimoto to Present at Virtual Fall Investor Summit on November 18

Arcimoto to Present at Virtual Fall Investor Summit on November 18

EUGENE, Ore.–(BUSINESS WIRE)–
Arcimoto, Inc.® (NASDAQ: FUV), makers of the Fun Utility Vehicle® (FUV®), Rapid Responder™, and Deliverator™—affordable, practical, and joyful pure electric vehicles for everyday commuters and fleets—today announced that it will be presenting at the Virtual Fall Investor Summit on Wednesday, November 18 at 1:00 p.m. EST.

Mark Frohnmayer, Chief Executive Officer of Arcimoto, will present virtually to an online audience and will also be available for one-on-one meetings with investors. A webcast of Arcimoto’s presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2038/38418.

Recent Company highlights include:

  • Partnered with DHL to provide nationwide home delivery of the FUV
  • Resumed production and delivery of Fun Utility Vehicles after suspending production in March due to pandemic.
  • Introduced the Roadster, the newest concept prototype built on the three-wheel Arcimoto platform.
  • Teamed up with the Baltimore-Maryland 2026 World Cup Host Committee in order to promote Baltimore as a host city for the upcoming 2026 FIFA World Cup
  • Started Deliverator pilot program with Wahlburgers Key West

About the Virtual Fall Investor Summit

On November 16-18, Investor Summit Virtual will convene 500 attendees, 75 issuers, 30 buy-side speakers, 3 Nights of entertainment and networking in virtual lounges, and 1 stock pitch competition covering the best investment opportunities in the market.

About Arcimoto, Inc.

Arcimoto (NASDAQ: FUV) develops and manufactures ultra-efficient and affordable electric vehicles to help the world shift to a sustainable transportation system. Now available to preorder customers on the West Coast, the Arcimoto FUV is purpose-built for everyday driving, transforming commutes into pure-electric joyrides. Available for preorder, the Deliverator and Rapid Responder provide last-mile delivery and emergency response functionality, respectively, at a fraction of the cost and environmental impact of traditional gas-powered vehicles. Every Arcimoto vehicle is built at the Arcimoto Manufacturing Plant in Eugene, Oregon. For more information, please visit Arcimoto.com

Public Relations Contact:

Megan Kathman

(651) 785-3212

[email protected]

Investor Relations Contact:

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Alternative Energy Energy Automotive Alternative Vehicles/Fuels

MEDIA:

Logo
Logo
Posted on

RBC Global Asset Management Inc. announces RBC ETF cash distributions for November 2020

Canada NewsWire

TORONTO, Nov. 13, 2020 /CNW/ – RBC Global Asset Management Inc. (“RBC GAM Inc.”) today announced November 2020 cash distributions for unitholders of RBC ETFs, as follows:


FUND NAME


FUND TICKER


 CASH DISTRIBUTION PER UNIT

RBC 1-5 Year Laddered Canadian Bond ETF

RLB

$0.036

RBC 1-5 Year Laddered Corporate Bond ETF

RBO

$0.035

RBC Target 2021 Corporate Bond Index ETF

RQI

$0.055

RBC Target 2022 Corporate Bond Index ETF

RQJ

$0.031

RBC Target 2023 Corporate Bond Index ETF

RQK

$0.040

RBC Target 2024 Corporate Bond Index ETF

RQL

$0.040

RBC Target 2025 Corporate Bond Index ETF

RQN

$0.035

RBC Target 2026 Corporate Bond Index ETF

RQO

$0.035

RBC Target 2027 Corporate Bond Index ETF

RQP

$0.035

RBC Canadian Discount Bond ETF

RCDB

$0.025

RBC PH&N Short Term Canadian Bond ETF

RPSB

$0.025

RBC Short Term U.S. Corporate Bond ETF

RUSB

$0.040

RBC Short Term U.S. Corporate Bond ETF (USD Units)*

RUSB.U

$0.031

RBC BlueBay Global Diversified Income (CAD Hedged) ETF

RBDI

$0.020

RBC Canadian Preferred Share ETF

RPF

$0.080

RBC Quant Canadian Dividend Leaders ETF

RCD

$0.055

RBC Canadian Bank Yield Index ETF

RBNK

$0.060

RBC Quant U.S. Dividend Leaders ETF

RUD

$0.075

RBC Quant U.S. Dividend Leaders ETF (USD Units)*

RUD.U

$0.058

RBC Quant U.S. Dividend Leaders (CAD Hedged) ETF

RUDH

$0.060

RBC U.S. Banks Yield Index ETF

RUBY

$0.020

RBC U.S. Banks Yield Index ETF (USD Units)*

RUBY.U

$0.015

RBC U.S. Banks Yield (CAD Hedged) Index ETF

RUBH

$0.020

RBC Quant European Dividend Leaders ETF

RPD

$0.010

RBC Quant European Dividend Leaders ETF (USD Units)*

RPD.U

$0.008

RBC Quant European Dividend Leaders (CAD Hedged) ETF

RPDH

$0.020

RBC Quant EAFE Dividend Leaders ETF

RID

$0.075

RBC Quant EAFE Dividend Leaders ETF (USD Units)*

RID.U

$0.058

RBC Quant EAFE Dividend Leaders (CAD Hedged) ETF

RIDH

$0.080

RBC Quant Emerging Markets Dividend Leaders ETF

RXD

$0.053

RBC Quant Emerging Markets Dividend Leaders ETF (USD Units)*

RXD.U

$0.041

* Cash distribution per unit ($) amounts are USD for RUSB.U, RUD.U, RUBY.U, RPD.U, RID.U, and RXD.U

Unitholders of record on November 20, 2020 will receive distributions payable on November 30, 2020.

The RBC Target 2020 Corporate Bond Index ETF (RQH) is scheduled to mature effective the close of business today, and the final net asset value of RQH will be distributed to remaining unitholders on a pro rata basis.

The RBC Strategic Global Dividend Leaders ETF (RLD), RBC Strategic Global Equity Leaders ETF (RLE), RBC Quant Global Infrastructure Leaders ETF (RIG in CAD and RIG.U in USD), RBC Quant Global Real Estate Leaders ETF (RGRE in CAD and RGRE.U in USD), and RBC 6-10 Year Laddered Canadian Corporate Bond ETF (RMBO) (each a “Terminating ETF”) are scheduled to terminate effective on or about November 27, 2020. Upon termination, the final net asset value of each Terminating ETF will be announced and distributed to remaining unitholders of each respective Terminating ETF on a pro rata basis.

For further information regarding RBC ETFs, please visit www.rbcgam.com/etfs.

Commissions, management fees and expenses all may be associated with investments in exchange-traded funds (ETFs). Please read the applicable prospectus or ETF Facts document before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. ETF units are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns. RBC ETFs do not seek to return any predetermined amount at maturity. Index returns do not represent RBC ETF returns. RBC ETFs are managed by RBC GAM Inc., a member of the RBC GAM group of companies and an indirect wholly-owned subsidiary of Royal Bank of Canada.

About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 86,000+ employees who bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada’s biggest bank, and one of the largest in the world based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our 17 million clients in Canada, the U.S. and 34 other countries. Learn more at rbc.com.‎

We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/community-social-impact.

About RBC Global Asset Management

RBC Global Asset Management (RBC GAM) is the asset management division of Royal Bank of Canada (RBC) and includes money managers BlueBay Asset Management and Phillips, Hager & North Investment Management. RBC GAM is a provider of global investment management services and solutions to institutional, high-net-worth and individual investors through separate accounts, pooled funds, mutual funds, hedge funds, exchange-traded funds and specialty investment strategies. The RBC GAM group of companies manage approximately $520 billion in assets and have approximately 1,400 employees located across Canada, the United States, Europe and Asia.

SOURCE RBC Global Asset Management Inc.

Posted on

Conagra Brands Announces its 2020 Zero Waste Champions

Eight Facilities Recognized for Achieving 95 Percent Waste Diversion

PR Newswire

CHICAGO, Nov. 13, 2020 /PRNewswire/ — In celebration of America Recycles Day, Conagra Brands is honoring its employees who are keeping materials out of landfills through innovative recycling and waste reduction measures. Eight Conagra facilities across the United States and Mexico have been awarded Zero Waste Champion status for diverting more than 95 percent of waste materials from landfills. These facilities helped Conagra achieve an 84 percent companywide waste diversion rate in the 2020 fiscal year.

Conagra emphasizes a systematic and strategic approach to reduce the amount of waste its facilities generate to maximize the use of resources for the future. For unavoidable waste, comprised mainly of food and packaging materials, Conagra encourages innovative ways to donate, reuse or recycle, such as composting or diverting organic waste to animal feed. The Zero Waste Champion facilities set standards to advance the company’s zero waste efforts and serve as a model for all production facilities to follow.

“We commend our employees’ ingenuity and dedication to finding solutions that reduce landfill waste,” said Dave Biegger, executive vice president and chief supply chain officer at Conagra Brands. “Our Zero Waste Champion facilities demonstrate Conagra’s commitment to finding new ways to be more environmentally responsible and nourish the planet.”

This year’s honorees include frozen, snacks, international and grocery manufacturing facilities. The 2020 Zero Waste Champion facilities are:

  • Brookston, Ind.
  • Hamburg, Iowa
  • Irapuato, Mexico
  • Lakeview, Iowa
  • Mankato, Minn.
  • Maple Grove, Minn.
  • Oakdale, Calif.
  • Waseca, Minn.

About Conagra Brands




Conagra Brands, Inc. (NYSE: CAG), headquartered in Chicago, is one of North America’s leading branded food companies. Guided by an entrepreneurial spirit, Conagra Brands combines a rich heritage of making great food with a sharpened focus on innovation. The company’s portfolio is evolving to satisfy people’s changing food preferences. Conagra’s iconic brands, such as Birds Eye®, Duncan Hines®, Healthy Choice®, Marie Callender’s®, Reddi-wip®, and Slim Jim®, as well as emerging brands, including Angie’s® BOOMCHICKAPOP®, Duke’s®, Earth Balance®, Gardein®, and Frontera®, offer choices for every occasion. For more information, visit www.ConagraBrands.com.

For all media inquiries, please contact:

Tim Wrona, Conagra Brands
312-549-5400
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/conagra-brands-announces-its-2020-zero-waste-champions-301172215.html

SOURCE Conagra Brands, Inc.